Related Experiment Video
Updated: May 14, 2026
08:07
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
Published on: September 6, 2017
HLA-G 2012 conference: the 15-year milestone update.
M Loustau1, H Wiendl, S Ferrone
1CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France.
Tissue Antigens
|January 26, 2013
Summary
The human leukocyte antigen (HLA)-G molecule, known for immune tolerance, has expanded roles beyond the maternal-fetal interface. Recent research highlights its function in cancer and regulatory cells, crucial for clinical applications.
Area of Science:
- Immunology
- Molecular Biology
- Cell Biology
Background:
- The non-classical human leukocyte antigen (HLA) Class I molecule, HLA-G, is primarily recognized for its critical role in immune tolerance at the maternal-fetal interface, preventing fetal rejection.
- Emerging research indicates that HLA-G possesses functions extending significantly beyond its established role in pregnancy.
Framework:
- The Sixth International Conference on HLA-G (Paris, 2012) convened 180 international experts to discuss recent advancements.
- Presentations covered novel insights into HLA-G's mechanisms of action, regulatory cell interactions, and implications in oncological research.
Implementation:
- Focus on new mechanisms of action involving regulatory cells and their interaction with HLA-G.
- Exploration of HLA-G's relevance and potential therapeutic applications in cancer immunology.
- Detailed investigation into the molecular structure and diverse functions of HLA-G.
Implications:
- Understanding HLA-G's multifaceted roles is key to developing new clinical strategies.
- Advances in HLA-G research hold promise for improving transplant outcomes and cancer therapies.
- The findings underscore the importance of continued investigation into HLA-G's immunomodulatory properties for clinical translation.
